RT Journal Article SR Electronic T1 Analysis of the Curative Effect of Preoperative Intra-Arterial Infusion Chemoembolization on Stage IB2-IIB Uterine Cervix Cancer JF Chinese Journal of Clinical Oncology JO Cancer Biol Med FD China Anti-Cancer Association SP 443 OP 447 DO 10.1007/s11805-008-0443-2 VO 5 IS 6 A1 Huashu Li A1 Fuxiang Liu A1 Guohe Zhou A1 Zhaoxia Mo YR 2008 UL http://www.cancerbiomed.org/content/5/6/443.abstract AB OBJECTIVE To investigate the short-term and long-term therapeutic efficacy of preoperative intra-arterial infusion chemo-embolization on stage IB2-IIB uterine cervix cancer (UCC).METHODS A total of 143 patients with Stage IB2-IIB UCC were divided into a clinical trial group and a control group. The patients in the clinical trial group (n = 86) were treated with a combined therapy, i.e., preoperative intra-arterial infusion chemo-embolization, surgical therapy and postoperative radiotherapy, and those in the control group (n = 57) were given surgical therapy and post-operative radiotherapy. The adverse effects, changes in local lesion and pathological examinations of the cancer, and the state during the surgery were observed after the intra-arterial infusion chemo-embolization. The survival rate and recurrence rate between the two groups were compared.RESULTS The total effective rate of the intra-arterial infusion chemo-embolization on Stage IB2-IIB UCC was 93.02%. The treatment could reduce tumor size, bring about retro-conversions of the clinical stage of the tumors and pathological grade of the cancer cells, and decrease the quantity of intra-operative blood loss as well as the operating time. It could significantly improve the 5-year survival rate (P< 0.05), and reduce the 2 and 5-year tumor recurrence rates (P < 0.05). Moreover, its side effects were little.CONCLUSION Preoperative intra-arterial infusion chemo-embolization can create conditions for radical operation, lower the postoperative recurrence rate, and improve the prognosis in the patients with UCC. It is an effective therapy in treating UCC.